1
/
5

Designed to be similar, built for change

Address rising treatment costs without compromising on efficacy and safety1-3

YUSIMRY™ (adalimumab-aqvh) is a multi-indication biosimilar* to HUMIRA® (adalimumab). YUSIMRY is indicated for use across multiple rheumatologic, gastroenterologic, and dermatologic indications, including:

  • Rheumatoid Arthritis
  • Juvenile Idiopathic Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Crohn’s Disease
  • Ulcerative Colitis
  • Plaque Psoriasis
  • Hidradenitis Suppurativa

WARNING: SERIOUS INFECTIONS AND MALIGNANCY
See prescribing information for complete boxed warning.
Patients treated with YUSIMRY are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue YUSIMRY if a patient develops a serious infection or sepsis.

REFERENCES:

1. YUSIMRY™ (adalimumab-aqvh) prescribing information. Coherus BioSciences, Inc. 2. Mulcahy A, Buttorff C, Finegold K, et al. Projected US savings from biosimilars, 2021-2025. Am J Manag Care. 2022;28(7):329-335. 3. Boccia R, Jacobs I, Popovian R, de Lima Lopes Jr G. Can biosimilars help achieve the goals of US health care reform? Cancer Manag Res. 2017;9:197-205.

YUSIMRY quick-hit

Designed to be similar, built for change1-4

Address rising treatment costs without compromising on efficacy and safety1-4

YUSIMRY™ (adalimumab-aqvh) is a multi-indication biosimilar* to HUMIRA® (adalimumab injection). YUSIMRY is indicated for use across multiple gastroenterologic, rheumatologic, and dermatologic indications, including2:

  • Ankylosing Spondylitis
  • Crohn’s Disease
  • Juvenile Idiopathic Arthritis
  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Ulcerative Colitis
  • Hidradenitis Suppurativa

WARNING: SERIOUS INFECTIONS AND MALIGNANCY
See full prescribing information for complete boxed warning.
Patients treated with YUSIMRY are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue YUSIMRY if a patient develops a serious infection or sepsis.

YUSIMRY quick-hit

Designed to be similar, built for change1-4

Address rising treatment costs without compromising on efficacy and safety1-4

YUSIMRY™ (adalimumab-aqvh) is a multi-indication biosimilar* to HUMIRA® (adalimumab injection). YUSIMRY is indicated for use across multiple gastroenterologic, rheumatologic, and dermatologic indications, including2:

  • Ankylosing Spondylitis
  • Crohn’s Disease
  • Juvenile Idiopathic Arthritis
  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Ulcerative Colitis
  • Hidradenitis Suppurativa

WARNING: SERIOUS INFECTIONS AND MALIGNANCY
See full prescribing information for complete boxed warning.
Patients treated with YUSIMRY are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue YUSIMRY if a patient develops a serious infection or sepsis.

YUSIMRY quick-hit

Designed to be similar, built for change1-4

Address rising treatment costs without compromising on efficacy and safety1-4

YUSIMRY™ (adalimumab-aqvh) is a multi-indication biosimilar* to HUMIRA® (adalimumab injection). YUSIMRY is indicated for use across multiple gastroenterologic, rheumatologic, and dermatologic indications, including2:

  • Ankylosing Spondylitis
  • Crohn’s Disease
  • Juvenile Idiopathic Arthritis
  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Ulcerative Colitis
  • Hidradenitis Suppurativa

WARNING: SERIOUS INFECTIONS AND MALIGNANCY
See full prescribing information for complete boxed warning.
Patients treated with YUSIMRY are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue YUSIMRY if a patient develops a serious infection or sepsis.

YUSIMRY quick-hit

Designed to be similar, built for change1-4

Address rising treatment costs without compromising on efficacy and safety1-4

YUSIMRY™ (adalimumab-aqvh) is a multi-indication biosimilar* to HUMIRA® (adalimumab injection). YUSIMRY is indicated for use across multiple gastroenterologic, rheumatologic, and dermatologic indications, including2:

  • Ankylosing Spondylitis
  • Crohn’s Disease
  • Juvenile Idiopathic Arthritis
  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Ulcerative Colitis
  • Hidradenitis Suppurativa

WARNING: SERIOUS INFECTIONS AND MALIGNANCY
See full prescribing information for complete boxed warning.
Patients treated with YUSIMRY are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue YUSIMRY if a patient develops a serious infection or sepsis.

YUSIMRY quick-hit

Designed to be similar, built for change1-4

Address rising treatment costs without compromising on efficacy and safety1-4

YUSIMRY™ (adalimumab-aqvh) is a multi-indication biosimilar* to HUMIRA® (adalimumab injection). YUSIMRY is indicated for use across multiple gastroenterologic, rheumatologic, and dermatologic indications, including2:

  • Ankylosing Spondylitis
  • Crohn’s Disease
  • Juvenile Idiopathic Arthritis
  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Ulcerative Colitis
  • Hidradenitis Suppurativa

WARNING: SERIOUS INFECTIONS AND MALIGNANCY
See full prescribing information for complete boxed warning.
Patients treated with YUSIMRY are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Discontinue YUSIMRY if a patient develops a serious infection or sepsis.

YUSIMRY quick-hit

The biosimilar benefit

A biosimilar is a highly similar version of a reference biologic with no clinically meaningful differences in safety, purity, and potency. Biologics generally cannot be copied exactly, because the products usually contain a mix of many slight variations of a protein, and this mix is never exactly the same in each dose or batch of the product. This means that biologics cannot be copied exactly, and that is why biosimilars are not identical to the original biologic. The FDA carefully reviews the differences between the original biologic and the biosimilar to ensure that biosimilars are as safe and effective as the reference biologics.

Biosimilars were developed to2:

  • Provide you and your patients with more treatment options
  • Lower out-of-pocket costs for your patients
  • Reduce healthcare system spending

As of January 2023, more than 40 biosimilars have been approved by the FDA across a wide range of therapeutic areas.3

Biosimilars are projected to save the healthcare system approximately $60 billion in 2023, for a 5-year total of $153 billion.4

*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of YUSIMRY has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information.1

REFERENCES:

1. US Food and Drug Administration. Biological Product Definitions. 2022. Accessed April 25, 2023. https://www.fda.gov/files/drugs-published-Biological-Product-Definitions.pdf 2. Dougherty MK, Zineh I, Christl L. Perspectives on the current state of the biosimilar regulatory pathway in the United States. Clin Pharmacol Ther. 2018;103(1):36-39. 3. US Food and Drug Administration. Biosimilar Product Information. Accessed April 25, 2023. https://www.fda.gov/drugs/biosimilars-biosimilar-product-information 4. Mulcahy A, Buttorff C, Finegold K, et al. Projected US savings from biosimilars, 2021-2025. Am J Manag Care. 2022;28(7):329-335.

Proven biosimilarity to HUMIRA1

In biosimilar development, rigorous FDA approval requirements ensure that biosimilars establish similarity with no clinically meaningful differences from their reference product in terms of safety, purity and potency.2


YUSIMRY meets all FDA-required criteria to confirm similarity to HUMIRA1:

REFERENCES:

1. YUSIMRY™ (adalimumab-aqvh) prescribing information. Coherus BioSciences, Inc. 2. US Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry. April 2015. Accessed April 25, 2023. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference

No clinically meaningful differences from HUMIRA1

YUSIMRY (adalimumab-aqvh) showed no clinically meaningful differences from HUMIRA (adalimumab) in terms of efficacy and safety.1

  • No clinically significant differences between YUSIMRY and HUMIRA were established.

  • No clinically significant differences in adverse events were observed between YUSIMRY and HUMIRA.

  • Pharmacokinetic equivalence was proven in a trial of healthy adults.

REFERENCES:

1. YUSIMRY™ (adalimumab-aqvh) prescribing information. Coherus BioSciences, Inc.

YUSIMRY Solutions™

YUSIMRY Solutions™ is on its way soon! YUSIMRY Solutions™ is a co-pay savings program for eligible commercial patients.

The YUSIMRY Pen

  • Citrate-free formulation2

  • Latex-free design1

  • Thin wall, 29-gauge needle2

  • Identical dosing schedule to low-concentration HUMIRA1,3

More about YUSIMRY

REFERENCES:

1. YUSIMRY™ (adalimumab-aqvh) prescribing information. Coherus BioSciences, Inc. 2. Nash P, Vanhoof J, Hall S, et al. Randomized crossover comparison of injection site pain with 40 mg/0.4 or 0.8 mL formulations of adalimumab in patients with rheumatoid arthritis. Rheumatol Ther. 2016;3:257-270. 3. Humira(adalimumab) prescribing information. AbbVie Inc.